HONOLULU e PRAGA--(BUSINESS WIRE)--SOTIO, una società biotecnologica del Gruppo PPF, ha presentato oggi i risultati relativi a SOV02 – la sperimentazione clinica di fase II di DCVAC/OvCa, un prodotto per immunoterapia cellulare attiva somministrato a pazienti affette da carcinoma ovarico ricorrente – nel corso della 50a edizione dell’Annual Meeting on Women’s Cancer organizzato dalla Society of Gynecologic Oncology (SGO). L’analisi finale di SOV02 mostra che DCVAC/OvCa riduce il rischio di mort
06:05
HONOLULU/PRAG--(BUSINESS WIRE)--SOTIO, ein Biotechnologieunternehmen der PPF Group, präsentierte die Ergebnisse von SOV02, einer klinischen Phase-II-Studie zur Bewertung von DCVAC/OvCa, einem aktiven zellulären Immuntherapieprodukt, bei rezidivierendem Eierstockkrebs auf dem 50. Jahrestreffen 2019 von SGO zum Stand von Krebs bei Frauen. Die endgültige Analyse von SOV02 zeigt, dass DCVAC/OvCa das Sterberisiko im Vergleich zu Patientinnen, die kein DCVAC/OvCa erhielten, signifikant senkte. Die Er
06:03
HONOLULU et PRAGUE--(BUSINESS WIRE)--SOTIO, une société biotechnologique détenue par le groupe PPF, a présenté aujourd’hui les résultats de SOV02, son essai clinique de Phase II évaluant le DCVAC/OvCa, un produit d'immunothérapie cellulaire active, effectué sur des patientes atteintes d'un cancer ovarien récurrent, lors du 50e congrès annuel (édition 2019) de la SGO consacré au cancer chez la femme. L'analyse finale de l'essai SOV02 montre que le DCVAC/OvCa diminue significativement le risque d
05:53
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced today the U.S. Food and Drug Administration (FDA) has approved ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth. ZULRESSO is expected to be
01:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. 2018 and Recent Highlights Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for claims which have the potential to cover voclosporin’s method of use and dosing protocol for lup
Tue Mar 19, 2019 22:02
HONOLULU & PRAGUE--(BUSINESS WIRE)--SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50th Annual Meeting on Women's Cancer today. Final analysis of SOV02 shows that DCVAC/OvCa decreased the risk of death significantly compared to patients who did not receive DCVAC/OvCa. Clinical trial results were presented durin
Tue Mar 19, 2019 22:00
NEWTON, Mass.--(BUSINESS WIRE)--Data analysis leveraging Cheetah Medical technology was presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM)
Tue Mar 19, 2019 20:47
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock, at a purchase price of $2.50 per share, for aggr
Tue Mar 19, 2019 19:00
休斯敦--(BUSINESS WIRE)--(美国商业资讯) -- SpinalCyte, LLC是一家总部位于德克萨斯州的再生医学公司，专注于采用人类皮肤成纤维细胞(HDFs)进行椎间盘再生。该公司今天宣布，其首席执行官Pete O’Heeron将于欧洲中部时间2019年3月27日（周三）下午3:00在奥地利维也纳召开的China Focus @ Europe Vienna上进行呈报。 O’Heeron先生将在呈报中讨论SpinalCyte的全球焦点，并提供SpinalCyte成纤维细胞疗法技术CybroCell™的临床及商业更新。SpinalCyte的成纤维细胞疗法技术持有2项已颁发的中国专利和3项审批中的中国专利。I/II期CybroCell™研究数据显示，在12个月终点之后，疼痛缓解和椎间盘高度均有持续改善。公司正准备在获得FDA核准其在研新药方案后继续进行临床试验和开发。 关于China Focus @ Europe 自从近期中国药品审批流程改革以来，中国的临床试验和新药审批已经加快。去年获得核准的药品和生物技术产品分别达到破纪录的34个和5个。此举向全世界的药品开发公司开
Tue Mar 19, 2019 17:38
休士頓--(BUSINESS WIRE)--(美國商業資訊) -- SpinalCyte, LLC是總部位於德州的再生醫學公司，專注於採用人類皮膚纖維母細胞(HDFs)進行椎間盤再生。該公司今天宣佈，執行長Pete O’Heeron將於歐洲中部時間2019年3月27日（週三）下午3:00在奧地利維也納召開的China Focus @ Europe Vienna上發表報告。 O’Heeron先生將在報告中討論SpinalCyte的全球焦點，並提供SpinalCyte纖維母細胞療法技術CybroCell™的臨床及商業最新動態。SpinalCyte的纖維母細胞療法技術持有2項已頒發的中國專利和3項審核中的中國專利。第一/二期CybroCell™研究資料顯示，在12個月終點之後，疼痛緩解和椎間盤高度均持續改善。公司正準備在獲得FDA核准其研究性新藥物試驗計畫書後繼續進行臨床試驗和開發。 關於China Focus @ Europe 自從近期中國藥品審核流程改革以來，中國的臨床試驗和新藥批准已經加快。去年獲得核准的藥品和生物科技產品分別達到破紀錄的34個和5個。此舉向全世界的藥品開發公司開啟了
Tue Mar 19, 2019 17:37
CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® to Host First Annual International Congress on the Future of Neurology™
Tue Mar 19, 2019 17:26
SALT LAKE CITY--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/anticancer?src=hash" target="_blank"gt;#anticancerlt;/agt;--SignPath Pharma, Inc. reported in the March issue of Anticancer Research* that its proprietary intravenous liposomal curcumin (LipoCurc™) concentrates very intensely in the malignant plasma cells that cause multiple myeloma. LipoCurc™ infusion, which achieves blood levels of curcumin in humans that are 1000 – 2000 times more than standard oral curcumin, then concentrates...
Tue Mar 19, 2019 16:47
JENKINTOWN, Pa.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/HCC?src=hash" target="_blank"gt;#HCClt;/agt;--SFA Therapeutics today announced approval of the second key U.S. patent derived from its research & development program, which utilizes microbiome-derived metabolite small molecules as drugs to modulate the body’s anti-inflammatory and immune systems (USPTO #10,231,941). As a result of this new patent, targeting Ffar2 (GPR43) and Ffar3 (GPR441) and down-regulation of NF-ĸB, the...
Tue Mar 19, 2019 16:36
ESPOO, Finnland--(BUSINESS WIRE)--Mobidiag Ltd., ein kommerzielles Molekulardiagnostikunternehmen, das sich mit der Problematik der Verbreitung von Antibiotikaresistenzen befasst, nimmt vom 13. bis 16. April 2019 am 29. Europäischen Kongress für klinische Mikrobiologie und Infektionskrankheiten (ECCMID) in Amsterdam, Niederlande, teil. Organisiert von Europas führender Gesellschaft für klinische Mikrobiologie und Infektionskrankheiten, versammelt die jährliche ECCMID-Konferenz führende Experten
Tue Mar 19, 2019 16:32
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Patient Enrollment Completion for Rex Medical REVEAL Peripheral Atherectomy Trial
Tue Mar 19, 2019 16:14
DUBLIN--(BUSINESS WIRE)--The "Amblyopia Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. Amblyopia Global Clinical Trials Review, H2, 2018" provides an overview of Amblyopia clinical trials scenario. This report provides top line data relating to the clinical trials on Amblyopia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease
Tue Mar 19, 2019 16:00
PRINCETON, N.J.--(BUSINESS WIRE)--“Own the Future,” focuses on the innovative solutions for driving efficiency, improving quality, and mitigating risk in outsourced clinical trials
Tue Mar 19, 2019 15:00
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo announces the initiation of its pivotal Phase 2b/3 clinical study, ZEPHYR, investigating livoletide in patients with Prader-Willi syndrome.
Tue Mar 19, 2019 14:30
DUBLIN--(BUSINESS WIRE)--The "Bone Cancer Treatment Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. The global bone cancer treatment market was valued at USD 62,865.6 million in 2018, and it is estimated to be valued at USD 83,770.9 million in 2024, while witnessing a CAGR of 4.93%. Certain factors that are driving the market growth include increasing incidence of bone cancer, and increasing government initiatives for bone cancer
Tue Mar 19, 2019 14:26
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Tue Mar 19, 2019 14:00
ESPOO, Finlandia--(BUSINESS WIRE)--Mobidiag Ltd., una compañía de diagnóstico molecular en etapa comercial que se ocupa de la propagación de la resistencia a los antimicrobianos, asistirá al 29º Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas (ECCMID), que se celebrará en Ámsterdam, Países Bajos, del 13 al 16 de abril de 2019. Organizado por los líderes europeos en microbiología clínica y enfermedades infecciosas, el congreso anual ECCMID reúne a los principales expertos de
Tue Mar 19, 2019 13:35
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018. “2018 was a transformative year for Magenta, as we progressed our first-in-class programs and achieved multiple clinical and preclinical milestones,” said Jason Gardner, D.
Tue Mar 19, 2019 13:30
ESPOO, Finland--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/ECCMID19?src=hash" target="_blank"gt;#ECCMID19lt;/agt;--Mobidiag will exhibit Amplidiag® and Novodiag® solutions at the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam.
Tue Mar 19, 2019 13:00
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa. The presentations will highli
Tue Mar 19, 2019 13:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b bivalent norovirus vaccine clinical trial. “The initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step towards our goal of developing a vaccine that can protect the most vulnerable patients from this highly infectious disease,” sa
Tue Mar 19, 2019 13:00
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (NASDAQ: CELG). The investor presentation is available on the SEC’s website at www.SEC.gov and on Bristol-Myers Squibb’s website at https://www.bms.com/investors.html. Highlights of the presentation include: The Celgene acquisition is a financi
Tue Mar 19, 2019 12:59
ESPOO, Finland--(BUSINESS WIRE)--Mobidiag Ltd., een commercieel moleculair diagnostisch bedrijf dat zich richt op de verspreiding van antimicrobiële resistentie, zal aanwezig zijn op het 29e European Congress of Clinical Microbiology & Infectieziekten (ECCMID) van 13 tot 16 april 2019 in Amsterdam, in Nederland. Georganiseerd door de leidende Europese samenleving in klinische microbiologie en infectieziekten, brengt de jaarlijkse ECCMID-bijeenkomst topexperts uit de hele wereld bij elkaar,
Tue Mar 19, 2019 12:08
ANDERNACH, Germany & BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment.
Tue Mar 19, 2019 11:30
ESPOO, Finlande--(BUSINESS WIRE)--Mobidiag Ltd., une société de diagnostic moléculaire au stade commercial axée sur la propagation de la résistance aux antimicrobiens, participera au 29e Congrès européen de microbiologie clinique et des maladies infectieuses (ECCMID) qui aura lieu à Amsterdam, aux Pays-Bas, du 13 au 16 avril 2019. Organisé par l’ESCMID (Société européenne de microbiologie clinique et de pathologies infectieuses), la réunion annuelle de l’ECCMID rassemble des experts renommés du
Tue Mar 19, 2019 11:25
ESPOO, Finlandia--(BUSINESS WIRE)--Mobidiag Ltd., società di diagnostica molecolare in fase commerciale impegnata nella lotta alla propagazione della resistenza antimicrobica, parteciperà al 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) di Amsterdam, nei Paesi Bassi, dal 13 al 16 aprile 2019. Curato dalla principale organizzazione attiva nel segmento delle malattie cliniche infettive e microbiologiche, il congresso annuale dell'ECCMID riunirà esperti di prim
Tue Mar 19, 2019 11:20
LONDON--(BUSINESS WIRE)--EMMAC Life Sciences Ltd (“EMMAC” or the “Company”), the European independent medical cannabis company, is pleased to announce that Medalchemy, EMMAC’s fully-licensed GMP certified laboratory in Alicante, Spain, has secured approval from the Spanish Health Authorities AEMPS to import medical cannabis for scientific research. This landmark announcement places Medalchemy at the forefront of medical cannabis research in Spain, and ensures EMMAC is well positioned to capital
Tue Mar 19, 2019 09:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). This approval is based on results from the Phase III IMpower133 study, which showed that Tecentriq in combination wit
Tue Mar 19, 2019 03:15
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
Mon Mar 18, 2019 22:05
LOS ANGELES--(BUSINESS WIRE)--Puma will present interim results from its Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the SGO meeting
Mon Mar 18, 2019 21:45
RICHMOND, Va.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/biotechnology?src=hash" target="_blank"gt;#biotechnologylt;/agt;--Virginia Bio, the statewide non-profit trade association for the life science industry, announced today that after seven years of service Jeff Gallagher CEO will step down from his position as CEO later this year, then will continue to serve the association on select special projects. A national search for a new CEO will begin immediately, conducted by the Virginia...
Mon Mar 18, 2019 20:00
HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/celltherapy?src=hash" target="_blank"gt;#celltherapylt;/agt;--SpinalCyte announced that Pete O’Heeron, Chief Executive Officer, will present at the China Focus @ Europe Vienna on Wednesday, March 27, 2019
Mon Mar 18, 2019 18:48
STRASBOURG, France--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Transgene?src=hash" target="_blank"gt;#Transgenelt;/agt;--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that it has secured a €20 million revolving credit facility with Natixis, the French Corporate and Investment bank. The credit facility will have a 30-month term and Transgene will be...
Mon Mar 18, 2019 18:45
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris : TNG) (Paris:TNG) société de biotechnologie qui conçoit et développe des immunothérapies à base de virus contre les cancers et les maladies infectieuses, annonce l’obtention d’une ligne de crédit renouvelable de 20 millions d'euros par la banque française Natixis. La facilité de crédit sera disponible pendant une durée de 30 mois et Transgene pourra tirer et rembourser cette ligne à sa main, jusqu’à la date d’échéa
Mon Mar 18, 2019 18:45
WHEELING, W. Va.--(BUSINESS WIRE)--The Health Plan of West Virginia, Inc., has brought in Kentmere Healthcare Consulting Corporation of Wilmington, Del. to increase quality and services
Mon Mar 18, 2019 16:52
NEW YORK--(BUSINESS WIRE)--TransPerfect Life Sciences, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced that Clinipace has selected TransPerfect’s Trial Interactive E-Feasibility and eTMF solutions as part of their ongoing initiative to further cultivate a flexible and responsive infrastructure to support clinical research. Clinipace is a global, full-service contract research organization (CRO
Mon Mar 18, 2019 16:00
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA (dapagliflozin) reduced the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo (15.2% vs 17.8%; HR 0.84, [95% CI 0.72-0.99]) in patients with type 2 diabetes (T2D) who had a prior heart attack (myocardial infarction). In another pre-specified sub-analysis, FARXIGA compared to placebo reduced the relative risk of hosp
Mon Mar 18, 2019 15:01
LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Laboratories Inc. today announced the hiring of Margaret Borys as Chief Commercial Officer (CCO) and Juan Carlos Lopez-Talavera, M.D.
Mon Mar 18, 2019 15:00
HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics announces $15 million of Class A common stock financings; Proceeds to fund start-up activities for current and future clinical trials
Mon Mar 18, 2019 15:00
BEDMINSTER, N.J.--(BUSINESS WIRE)--Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesday, March 19 at 2:30 PM PT in Dana Point, CA. As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition. Matinas is developin
Mon Mar 18, 2019 14:35
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF). Systemic sclerosis, also known as scleroderma, is a rare disease characterised by thickening and scarring of connective tis
Mon Mar 18, 2019 14:06
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,179,202 titled, “Systems and methods for cleaning body cavities and for endoscopic steering,” which protects the Company’s flagship product, the Pure-Vu® System. The Pure-Vu® Sy
Mon Mar 18, 2019 14:05
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Boston Heart Diagnostics, one of the leading disease management laboratories in the United States, today announced the publication of a new research study: “Cardiovascular Risk Factor Reduction in First Responders Resulting from and Individualized Lifestyle and Blood Test Program: A Randomized Controlled Trial”. Published in the Journal of Occupational and Environmental Medicine, the study demonstrated the clinical effectiveness of the Boston Heart Lifestyle
Mon Mar 18, 2019 14:00
OSAKA, Japan & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/ai?src=hash" target="_blank"gt;#ailt;/agt;--Ono Pharmaceutical and twoXAR have signed a collaboration to discover and develop treatments for an unmet need in a specific neurological disease.
Mon Mar 18, 2019 14:00
BRISBANE, Calif.--(BUSINESS WIRE)--The U.S. FDA has accepted the BLA filing of Aimmune Therapeutics’ AR101 for peanut allergy.
Mon Mar 18, 2019 14:00
WATERTOWN, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ENTA&src=ctag" target="_blank"gt;$ENTAlt;/agt;--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it has completed enrollment in two Phase 2 studies. The Phase 2 study of EDP-938 in RSV is a randomized, double-blind, placebo-controlled, human challenge study in healthy...
Mon Mar 18, 2019 13:30
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019
Mon Mar 18, 2019 13:30
ALPHARETTA, Ga.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/TNBC?src=hash" target="_blank"gt;#TNBClt;/agt;--CSI Laboratories adds newly approved VENTANA PD-L1 (SP142) Assay as a companion diagnostic test for TNBC patients for TENCENTRIQ(R).
Mon Mar 18, 2019 13:30
PASADENA, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24arwr&src=ctag" target="_blank"gt;$arwrlt;/agt;--Arrowhead Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease and plans to initiate in the second quarter of 2019
Mon Mar 18, 2019 13:30
QUEBEC CITY, Quebec--(BUSINESS WIRE)--IMV Inc. (IMV) (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Canadian bioresearch consortium CQDM has awarded a grant to a collaboration among IMV, Centre de recherche du CHU de Québec-Université Laval, and La Fondation du CHU de Québec (FCHUQc). Under the leadership of Yves Fradet, M.D., professor of surgery and researcher in cancer immunotherapy, and his team, in collaboration with IMV’s team , this project wi
Mon Mar 18, 2019 13:05
QUÉBEC, Québec--(BUSINESS WIRE)--IMV Inc. (IMV) (Nasdaq: IMV; TSX: IMV), une société d’immuno-oncologie de stade clinique annonce aujourd’hui que le consortium de recherche biopharmaceutique CQDM a octroyé une subvention pour un projet auquel collaboreront IMV, le Centre de recherche du CHU de Québec-Université Laval et la Fondation du CHU de Québec (FCHUQc). Le projet, mené sous la direction du Dr Yves Fradet, M.D., professeur de chirurgie et chercheur en immunothérapie du cancer et de son équ
Mon Mar 18, 2019 13:05
CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line results from the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration of AKB-9778 twice dai
Mon Mar 18, 2019 13:00
NEW ORLEANS, Louisiana--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD), ein führender Anbieter bahnbrechender Technologien zur Unterstützung der Herzfunktion und Hersteller der Herzpumpe Impella RP, gibt bekannt, dass die Überlebensdaten aus der 18-monatigen Post-Zulassungsstudie mit 42 Impella-RP-Patienten auf der 68. wissenschaftlichen Jahrestagung des American College of Cardiology (ACC) in New Orleans vorgelegt wurden. Impella RP ist die einzige perkutan angewendete Technologie zur Unterstützung de
Mon Mar 18, 2019 13:00
NEW ORLEANS, La.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/heartrecovery?src=hash" target="_blank"gt;#heartrecoverylt;/agt;--Impella RP Post-Approval Study Data Presented at ACC 2019. Data demonstrates survival benefit with the Impella RP Recover Right protocol.
Mon Mar 18, 2019 13:00
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to ret
Mon Mar 18, 2019 12:30
CAMBRIDGE, England--(BUSINESS WIRE)--Cambridge Based Vaccine Company ImmBio has entered a licensing agreement with the largest vaccine producer in China, CNBG to Co-Develop ImmBio’s Pnu
Mon Mar 18, 2019 11:00
FREMONT, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/STOs?src=hash" target="_blank"gt;#STOslt;/agt;--Verseon is launching a security token offering (STO) aiming to set a new standard for the 21st century public offering to a globally connected investor base. To make its STO available to investors around the globe, Verseon will use the technology and services of its subsidiary BlockRules Ltd. Using its innovative, computationally driven drug discovery platform, clinical-stage pharmaceutical...
Mon Mar 18, 2019 09:00
LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/STOs?src=hash" target="_blank"gt;#STOslt;/agt;--BlockRules, the blockchain fintech company enforcing complex compliance rules directly on the blockchain, today announces that the first security token powered by its technology will be for Verseon, a clinical-stage pharmaceutical company and BlockRules’ parent company. BlockRules will provide technology and services for token launch, issuance, and trading. “We wanted to structure our STO...
Mon Mar 18, 2019 09:00
LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the Oppenheimer 29th Annual Healthcare Conference. The Oppenheimer 29th Healthcare Conference is being held on March 19-20, 2019 at The Westin New York Grand Central Hotel in New Yo
Mon Mar 18, 2019 09:00
BOSTON--(BUSINESS WIRE)--Karuna announced the completion of a $68 million Series B financing round led by ARCH Venture Partners.
Mon Mar 18, 2019 09:00
NEW ORLEANS--(BUSINESS WIRE)--Late-breaking results presented and published today confirm that the HeartFlow® FFRct Analysis enables physicians to efficiently identify which patients despite symptoms suggestive of coronary artery disease (CAD) have a low risk of adverse cardiovascular events and can safely avoid invasive testing out to one year. These results from the ADVANCE trial were presented as a late breaking trial during the American College of Cardiology’s (ACC) 68th Annual Scientific S
Sun Mar 17, 2019 21:00
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt;--AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients.
Sun Mar 17, 2019 17:45
BOULDER, Colo.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CLVS&src=ctag" target="_blank"gt;$CLVSlt;/agt; lt;a href="https://twitter.com/hashtag/SGO2019?src=hash" target="_blank"gt;#SGO2019lt;/agt;--Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress
Sat Mar 16, 2019 18:45
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
Fri Mar 15, 2019 22:17
DUBLIN--(BUSINESS WIRE)--The "Clinical Trial Management Systems Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. The clinical trial management systems market was valued at USD 665.9 million in 2017. Although the market has been in its nascent stage for the last five years, it has currently established itself as a mature market in the North American region. Asia-Pacific is still experiencing a high growth rate, when compared to othe
Fri Mar 15, 2019 20:00
GREENVILLE, SC.--(BUSINESS WIRE)--Inova and Roswell Park Comprehensive Cancer Center Join KIYATEC Clinical Trial to Predict Patient Response to Cancer Drugs Prior to Treatment
Fri Mar 15, 2019 19:02
LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24LIVN&src=ctag" target="_blank"gt;$LIVNlt;/agt;--LivaNova will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during ACC 2019.
Fri Mar 15, 2019 15:00
BEDMINSTER, N.J.--(BUSINESS WIRE)--Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at a price to the public of $1.10 per share for expected gross proceeds of $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Mati
Fri Mar 15, 2019 14:45
SEATTLE--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CapsularPolysaccharideVaccines?src=hash" target="_blank"gt;#CapsularPolysaccharideVaccineslt;/agt;--According to Coherent Market Insights, the Typhoid fever vaccines market was valued at US$ 225.0 million in 2018, and is projected to exhibit a CAGR of 11.9% over the forecast period (2018–2026). Key Trends and Analysis of the Typhoid Fever Vaccines Market: Organizations such as World Health Organization (WHO), Gavi, Bill & Melinda...
Fri Mar 15, 2019 14:35
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces one oral poster presentation and two poster presentations at the upcoming American College of Cardiology 2019 Annual Meeting being held March 16-18, 2019 in New Orleans, LA. RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a co
Fri Mar 15, 2019 14:00
DUBLIN--(BUSINESS WIRE)--The "Acalabrutinib - Launch Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Acalabrutinib - Launch Insight, 2019 provides comprehensive insights about Acalabrutinib's launch. The report covers all the indications for which the Acalabrutinib is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning. The repor
Fri Mar 15, 2019 13:19
BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial...
Fri Mar 15, 2019 13:00
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investigational Device Exemption (IDE) pivotal trial results for its next-generation iStent inject® Trabecular Micro-Bypass System have been published in Ophthalmology. Resu
Fri Mar 15, 2019 13:00
DUBLIN--(BUSINESS WIRE)--The "Zocor - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Zocor - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Zocor covering the historical global sales and also provides the Zocor sales estimation during the forecasted period (2019-2021). The report also covers the patents information and
Fri Mar 15, 2019 12:27
DUBLIN--(BUSINESS WIRE)--The "Lyrica - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Lyrica - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Lyrica covering the historical global sales and also provides the Lyrica sales estimation during the forecasted period (2019-2021). The report also covers the patents information
Fri Mar 15, 2019 12:26
DUBLIN--(BUSINESS WIRE)--The "Uniflox - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Uniflox - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Uniflox covering the historical global sales and also provides the Uniflox sales estimation during the forecasted period (2019-2021). The report also covers the patents informa
Fri Mar 15, 2019 12:19
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου